Literature DB >> 8338008

Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients.

I W Black1, A P Hopkins, L C Lee, W F Walsh.   

Abstract

This study prospectively evaluated the role of transesophageal echocardiography (TEE) in screening for atrial thrombi before electrical cardioversion in 40 nonanticoagulated patients with nonvalvular atrial fibrillation (n = 33) or atrial flutter (n = 7). Transthoracic echocardiography did not detect atrial thrombus in any patient. TEE detected left atrial appendage thrombi in five patients (12%, p = 0.03), significantly associated with left ventricular systolic dysfunction (p = 0.02) and left atrial spontaneous echo contrast (p = 0.04). Cardioversion was cancelled in the five patients with thrombi and in two patients with spontaneous reversion before planned cardioversion. Cardioversion was successful in 25 (76%) of the 33 remaining patients. Cerebral embolism occurred 24 hours after successful cardioversion in one patient with atrial fibrillation and left ventricular dysfunction, who had left atrial spontaneous echo contrast, but no thrombus was detected by TEE before cardioversion. Repeat TEE after embolism showed a fresh left atrial appendage thrombus and increased left atrial spontaneous echo contrast. These results indicate that TEE improves the detection of left atrial appendage thrombi in candidates for cardioversion, in whom the procedure may be deferred. However, the exclusion by TEE of preexisting atrial thrombi before cardioversion does not eliminate the risk of embolism after cardioversion because of persistent atrial stasis and de novo thrombosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338008     DOI: 10.1016/0002-8703(93)91054-i

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

Review 1.  Cardioversion in atrial fibrillation: indications, thromboembolic prophylaxis, and role of transesophageal echocardiography.

Authors:  M L Main; A L Klein
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 2.  Why is warfarin underutilized in patients with atrial fibrillation?

Authors:  Greg C Flaker; John Schutz
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

3.  Cardioversion of atrial fibrillation.

Authors:  O M Jolobe
Journal:  Postgrad Med J       Date:  1996-02       Impact factor: 2.401

Review 4.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

5.  Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk.

Authors:  I Schnittger
Journal:  Br Heart J       Date:  1995-04

Review 6.  Computed Tomography Imaging in Atrial Fibrillation Ablation.

Authors:  Kavita Sharma; Jeffrey A Brinker; Charles A Henrikson
Journal:  J Atr Fibrillation       Date:  2011-05-04

7.  [TEE-guided cardioversion in patients with atrial fibrillation without previous anticoagulation].

Authors:  P Halbfass; A Plewan; K Dennig; C Kolb; C Schmitt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-09

8.  Left atrial appendage function in patients with atrial flutter.

Authors:  H Omran; W Jung; R Rabahieh; D MacCarter; S Illien; B Rang; A Hagendorff; R Schimpf; B Lüderitz
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

9.  Characteristics of pulmonary vein enlargement in non-valvular atrial fibrillation patients with stroke.

Authors:  Jung Myung Lee; Jong Youn Kim; Jaemin Shim; Jae Sun Uhm; Young Jin Kim; Hye-Jeong Lee; Hui-Nam Pak; Moon-Hyoung Lee; Boyoung Joung
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.